Supplementary Online Content

This supplementary material has been provided by the authors to give readers additional information about their work.

eTable 1. Pairwise Correlation Between Individual SEP-1 Sepsis Bundle Components for Patients with Community-onset Sepsis and Hospital-onset Sepsis

	Blood cultures	Lactate	Antibiotics	IV Fluids	2nd Lactate
Community-Onset Sepsis					
Lactate	0.57				
Antibiotics	0.61	0.42			
IV Fluids	-0.037	-0.045	-0.022		
2nd Lactate	0.065	0.045	0.029	-0.12	
Vasopressors	0.01	0.012	-0.015	0.012	0.024
Hospital-Onset Sepsis					
	Blood cultures	Lactate	Antibiotics	IV Fluids	2nd Lactate
Lactate	0.33				
Antibiotics	0.66	0.28			
IV Fluids	-0.038	-0.10	-0.0396		
2nd Lactate	0.068	0.036	0.098	-0.031	
Vasopressors	0.005	0.015	0.082	0.082	-0.001

Legend: Community-onset sepsis was defined by time zero of sepsis occurring in the emergency department. Hospital-onset sepsis was defined by time zero of sepsis occurring on an inpatient unit even if signs or symptoms of sepsis preceded admission.

8   **eTable 2.** Relative Risk of In-hospital Mortality Associated with Clinical Variables in the Raw
9   Cohorts with Community-onset and Hospital-onset Sepsis
10

	Community-Onset Sepsis n = 4108		Hospital-Onset Sepsis n = 2296	
	Relative Risk	p-value	Relative Risk	p-value
Age in years	**1.01**	**< 0.001**	**1.01**	**0.001**
ECI	**1.06**	**< 0.001**	**1.08**	**< 0.001**
Female	1.03	0.60	1.08	0.36
Postoperative	1.21	0.35	1.05	0.69
Pneumonia POA	**1.41**	**< 0.001**	1.19	0.09
UTI POA	**0.66**	**< 0.001**	**0.68**	**0.002**
SSTI POA	0.83	0.21	0.93	0.70
New Bacteremia	1.04	0.66	1.28	**0.032**
Immunosuppressed	**1.25**	**0.005**	**1.26**	**0.008**
Fever	**0.47**	**< 0.001**	**0.64**	**< 0.001**
Septic Shock	**1.84**	**< 0.001**	**1.27**	**0.005**
- Hypotension	0.92	0.26	0.97	0.73
- Elevated Lactate	**0.83**	**0.033**	1.25	0.10

11
12   **Legend:** POA, present on admission. UTI, urinary tract infection. SSTI, skin and/or soft tissue
13   infection. Bold font denotes a statistically significant standardized difference for an $\alpha = 0.05$.

14

15 **eTable 3.** Characteristics of the Total Sample Before and After Being Rebalanced on Propensity

16 for Treatment and Observable Characteristics

17

	Raw Total Sample			Rebalanced Total Sample		
	Treated	Untreated	SD	Treated	Untreated	SD
Time Zero of Sepsis (Hours*)	8.97	34.3	**-0.33**	6.55	8.45	**-0.025**
Age	65.6	63.3	**0.13**	65.9	66.1	-0.011
Female (%)	43.7	45.3	-0.033	43.6	44.68	-0.003
Elixhauser Comorbidities	4.91	5.14	**-0.076**	4.84	4.85	-0.003
Postoperative (%)	3.01	9.67	**-0.28**	1.98	1.98	0
Pneumonia POA† (%)	34.0	25.3	**0.19**	34.0	34.0	0
Urinary tract infection (%)	25.4	21.2	**0.10**	26.0	26.0	0
Skin / soft tissue infection (%)	7.99	6.03	**0.077**	7.88	6.53	0.053
New Bacteremia‡ (%)	14.6	14.5	0.003	14.6	15.8	-0.033
Immunosuppressed (%)	19.2	24.7	**-0.13**	18.3	18.3	0
Fever (%)	36.8	22.7	**0.31**	35.5	35.5	0
Septic Shock (%)	27.5	42.7	**-0.32**	27.2	27.2	0
- Hypotension	35.5	55.0	**-0.40**	35.8	35.8	0
- Elevated Serum Lactate*	28.7	17.2	**0.28**	29.1	27.8	0.029
Hospital 1 (%)	9.85	11.6	**-0.055**	9.49	9.49	0
Hospital 2 (%)	13.5	17.3	**-0.10**	13.2	13.2	0
Hospital 3 (%)	32.7	41.3	**-0.18**	32.9	32.9	0
Hospital 4 (%)	43.9	29.9	**0.29**	44.5	44.5	0

18

19 **Legend:** SD, standardized difference. POA, present on admission. Bold font denotes a

20 statistically significant standardized difference for an α = 0.05. * Hours from admission. †

21 Pneumonia POA was determined by diagnosis codes. ‡ New bacteremia was defined by positive

22 blood culture after time zero of sepsis in a patient who did not have a positive blood culture in

23 the preceding week. Possible skin contaminants were excluded. *** Elevated serum lactate was

24 defined as a value of >20 mmol/L at time of onset of sepsis or in the preceding 6 hours. To meet

25 the definition of shock, serum lactate needed to be 4 mmol/L or greater.

26 **eTable 4.** Relative Risk of In-hospital Mortality Associated with Clinical Variables in the Raw
27 Total Sample
28

	Relative Risk	95% Confidence Interval	p-value
SEP-1 Sepsis Bundle	0.99	(0.88, 1.12)	0.88
Hospital-Onset of Sepsis	1.05	(0.94, 1.17)	0.381
Age in years*	**1.01**	**(1.01, 1.01)**	**< 0.001**
Female	1.06	(0.96, 1.17)	0.28
Elixhauser Comorbidities*	**1.07**	**(1.05, 1.08)**	**< 0.001**
Postoperative	1.35	(0.88, 1.30)	0.48
Pneumonia POA	**1.35**	**(1.21, 1.50)**	**< 0.001**
Urinary Tract infection POA	**0.67**	**(0.58, 0.77)**	**< 0.001**
Skin / soft tissue infection POA	0.85	(0.68, 1.06)	0.16
New Bacteremia	1.12	(0.98, 1.28)	0.10
Immunosuppressed	**1.25**	**(1.11, 1.40)**	**< 0.001**
Fever	**0.51**	**(0.44, 0.59)**	**< 0.001**
Septic Shock	**1.55**	**(1.40, 1.72)**	**< 0.001**

29
30 **Legend:** POA, present on admission. * Relative risk is reported for incremental increase in 1
31 year of age or 1 additional Elixhauser comorbidity.

32 **eTable 5.** Results from Endogenous Treatment Effects Models Compared with
33 Unweighted/Unbalanced Regression
34

Treatment		ATET	NATE
SEP-1	MD	+0.10	-0.23
	VD	+0.26	-0.60
Blood Cultures	MD	-5.01	+0.97
	VD	-0.44	-0.28
Serum Lactate	MD	-2.68	+1.26
	VD	-0.004	+0.28
Antibiotics	MD	-3.83	-1.03
	VD	-0.45	-0.27
IV Fluids	MD	-0.57	+2.64
	VD	-0.23	-010

35
36 **Legend:** ATET, average treatment effect on the treated. NATE, naïve (i.e., unweighted /
37 unbalanced) treatment effect. MD, Mortality difference calculated as the average difference in
38 probabilities between the treated and untreated (unit is percentage points); VD, vasopressor days;
39 IV, intravenous.

40 **eTable 6.** Prespecified Sensitivity Analyses Evaluating Treatment Effect of the Complete SEP-1
41 Bundle in Different Cohorts*
42

Subgroup	Mortality Difference†	Vasopressor Days
Age ≥ 65	-0.01% (-3.88, 3.86)	**+0.37 (0.14, 0.60)**
Age < 65	+1.94% (-1.37, 5.26)	**+0.48 (0.21, 0.75)**
Pneumonia POA	-0.96% (-6.70, 4.77)	+0.59 (0.26, 0.92)
No Pneumonia POA	+1.30% (-1.40, 4.00)	+0.32 (0.11, 0.52)
Immunosuppressed	+4.63% (-1.53, 10.8)	**+0.86 (0.45, 1.28)**
Not Immunosuppressed	-0.61% (-3.42, 2.21)	**+0.26 (0.07, 0.45)**
New Bacteremia	+1.35% (-5.03, 7.72)	+0.45 (-0.09, 0.99)
No New Bacteremia	+0.23% (-2.62, 3.07)	**+0.38 (0.20, 0.57)**
Fever	+2.30% (-0.97, 5.56)	**+0.33 (0.07, 0.59)**
Afebrile	+0.53% (-2.93, 3.99)	**+0.40 (0.18, 0.62)**
Septic Shock	+2.19% (-3.05, 743)	**+0.55 (0.14, 0.97)**
Sepsis without Shock	-0.38% (-3.58, 2.82)	0.01 (-0.16, 0.19)

43
44 **Legend:** SEP-1 refers to the Early Management Bundle for Severe Sepsis / Septic Shock
45 (National Quality Forum #0500). * Dedicated propensity and outcomes models were run within
46 the subgroup of interest. Subgroup analyses excluded all encounters from outside the subgroup. †
47 Difference in probability of in-hospital death was estimated as the average treatment effect on
48 the treated and is expressed in percentage points.

49 **eTable 7.** Treatment Effects of SEP-1 Bundle Components in Different Cohorts*

50

		Blood Cultures	Lactate	Antibiotics	IV Fluids†
Age ≥ 65 **n = 2459**	MD	-9.58 (-200, 0.86)	-3.51 (-9.06, 2.03)	-3.84 (-8.81, 1.14)	-3.83 (-12.2, 4.51)
	VD	**-0.88 (-1.69, -0.07)**	0.15 (-0.28, 0.59)	**-0.42 (-0.82, -0.01)**	-0.18 (-0.86, 0.49)
Age < 65 **n = 2854**	MD	-2.37 (-8.19, 3.45)	-1.18 (-5.73, 3.38)	1.40 (-2.60, 5.40)	5.61 (-1.02, 12.2)
	VD	-0.48 (-1.00, 0.04)	-0.06 (-0.47, 0.35)	-0.18 (-0.54, 0.18)	-0.13 (-0.83, 0.57)
Pneumonia POA **n = 1613**	MD	-10.3 (-25.5, 4.91)	-2.41 (-11.0, 6.18)	-3.38 (-10.9, 4.13)	1.95 (-15.9, 19.8)
	VD	-0.26 (-0.90, 0.85)	0.31 (-0.31, 0.94)	-0.08 (-0.63, 0.46)	-0.14 (-1.72, 1.44)
No Pneumonia POA **n = 3975**	MD	-2.75 (-8.01, 2.50)	-2.27 (-6.43, 1.88)	-3.60 (-8.00, 0.82)	-2.61 (-8.83, 3.62)
	VD	**-0.58 (-1.08, -0.07)**	-0.09 (-0.44, 0.27)	**-0.61 (-0.99, -0.22)**	-0.35 (-0.90, 0.21)
Immunosuppressed **n = 1376**	MD	-3.60 (-14.7, 7.50)	-1.21 (-10.3, 7,85)	0.08 (-8.32, 8.47)	12.4 (-3.59, 28.4)
	VD	-0.24 (-0.99, 0.50)	0.25 (-0.40, 0.89)	**-0.75 (-1.50, -0.001)**	0.22 (-1.46, 1.91)
Non-immunosuppressed **n = 4352**	MD	-5.76 (-13.0, 1.47)	-3.01 (-7.39, 1.36)	-4.01 (-8.02, 0.01)	-1.97 (-8.18, 4.24)
	VD	**-0.79 (-1.42, -0.16)**	-0.03 (-0.38, 0.31)	**-0.38 (-0.70, -0.06)**	-0.43 (-0.97, 0.11)
New Bacteremia **n = 738**	MD	-13.9 (-28.4, 0.53)	-4.98 (-18.1, 8.12)	-4.33 (-12.5, 3.81)	-1.43 (-19.5, 16.6)
	VD	**-2.11 (-3.53, -0.69)**	-0.24 (-1.22, 0.74)	**-1.34 (-2.08, -0.60)**	-0.07 (-1.71, 1.58)
No New Bacteremia **n = 5476**	MD	-2.34 (-8.40, 3.73)	-2.11 (-6.13, 1.92)	-2.80 (-6.38, 0.77)	-0.04 (-6.22, 6.14)
	VD	-0.28 (-0.76, 0.21)	0.18 (-0.15, 0.51)	-0.20 (-0.49, 0.09)	-0.16 (-0.71, 0.39)
Fever **n = 1722**	MD	0.23 (-17.3, 17.7)	-4.62 (-14.0, 4.72)	-2.03 (-8.54, 4.48)	3.60 (-3.70, 10.9)
	VD	0.81 (-0.26, 1.87)	0.02 (-0.66, 0.69)	-0.25 (-0.77, 0.28)	0.28 (-0.68, 1.24)
Afebrile **n = 4225**	MD	-5.22 (-11.1, 0.64)	-3.47 (-7.92, 0.98)	-2.77 (-6.69, 1.14)	0.47 (-7.05, 7.98)
	VD	**-0.61 (-1.08, -0.15)**	0.01 (-0.31, 0.34)	**-0.38 (-0.69, -0.06)**	-0.36 (-1.03, 0.32)
Septic Shock **n = 2248**	MD	-4.58 (-14.5, 5.29)	-3.39 (-12.9, 6.20)	-6.54 (-13.7, 0.61)	-6.30 (-14.5, 1.94)
	VD	-0.55 (-1.50, 0.40)	0.11 (-0.62, 0.83)	-0.45 (-1.00, 0.10)	-0.61 (-1.32, 0.11)
Sepsis without Shock **n = 3164**	MD	-6.42 (-13.0, 0.11)	-3.63 (-7.95, 0.68)	-2.45 (-5.99, 1.10)	2.66 (-6.58, 11.9)
	VD	**-0.36 (-0.71, -0.003)**	-0.17 (-0.47, 0.13)	-0.11 (-0.31, 0.08)	0.19 (-0.40, 0.79)

51

52 **Legend:** MD, Mortality difference calculated as the average difference in probabilities between
53 the treated and untreated (unit is percentage points); VD, vasopressor days; 95% CI, 95%
54 confidence interval. POA, present on admission. * Dedicated propensity and outcomes models
55 were run within the subgroup of interest. Subgroup analyses excluded all encounters from
56 outside the subgroup. † Only measured among individuals in whom intravenous fluids were
57 indicated based on SEP-1 guidance

58 **eTable 8.** Treatment Effects of SEP-1 Sepsis Bundle and Components on 30-day In-hospital
59 Mortality in Total Sample and Rebalanced Cohorts with Community-onset & Hospital-onset
60 Sepsis
61

	Total Sample	Community-Onset Sepsis	Hospital-Onset Sepsis
	Risk Difference* (95% CI)	Risk Difference* (95% CI)	Risk Difference* (95% CI)
SEP-1 Bundle	+0.49 (-1.93, 2.90)	+0.67 (-2.16, 3.49)	+0.91 (-5.29, 7.11)
Blood cultures	-5.13 (-11.0, 0.74)	-5.98 (-15.2, 3.25)	-2.43 (-8.31, 3.45)
Serum Lactate	-1.86 (-5.63, 1.92)	-5.76 (-12.4, 0.88)	+0.44 (-4.94, 4.06)
Antibiotics	-3.78 (-7.67, 0.11)	-3.72 -8.90, 1.47)	-4.12 (-8.99, 0.74)
Intravenous Crystalloid	+1.14 (-4.07, 6.36)	+0.84 (-5.91, 7.59)	-4.63 (-15.1, 5.84)

62

63 **Legend:** 95% CI, 95% confidence interval. SEP-1 refers to the Early Management Bundle for
64 Severe Sepsis / Septic Shock (National Quality Forum #0500). * Mortality is expressed as an
65 absolute probability difference between the average of the treated and the average of the
66 untreated, expressed in terms of percentage points.

67 **eTable 9.** Treatment Effects of SEP-1 Sepsis Bundle and Components on Hospital Length of
68 Stay (Measured from Time Zero of Sepsis Until Discharge)
69

	Total Sample	Community-Onset Sepsis	Hospital-Onset Sepsis
	Length of Stay* (95% CI)	Length of Stay* (95% CI)	Length of Stay* (95% CI)
SEP-1 Bundle	-0.54 (-1.41, 0.33)	-0.79 (-1.93, 0.35)	-1.08 (-3.42, 1.27)
Blood cultures	-0.05 (-1.78, 1.69)	+1.43 (-0.72, 3.58)	-1.35 (-3.99, 1.28)
Serum Lactate	-0.28 (-1.43, 0.87)	-0.47 (-2.63, 1.69)	-0.99 (-2.84, 0.85)
Antibiotics	+0.26 (-0.65, 1.17)	+0.78 (-0.38, 1.93)	+0.42 (-1.28, 2.12)
Intravenous Crystalloid	-1.15 (-2.86, 0.55)	-0.71 (-2.73, 1.30)	+1.49 (-1.41, 4.38)

70

71 **Legend:** 95% CI, 95% confidence interval. SEP-1 refers to the Early Management Bundle for
72 Severe Sepsis / Septic Shock (National Quality Forum #0500). * Length of stay is expressed in
73 days from time zero of sepsis until discharge.

74 **eTable 10.** Treatment Effects of SEP-1 Sepsis Bundle and Components on Composite Outcome
75 of In-hospital Mortality or Discharge to Hospice
76

	Total Sample	Community-Onset Sepsis	Hospital-Onset Sepsis
	Risk Difference* (95% CI)	Risk Difference* (95% CI)	Risk Difference* (95% CI)
SEP-1 Bundle	-0.43 (-3.37, 2.52)	+0.08 (-3.39, 3.23)	-2.97% (-9.91, 3.96)
Blood cultures	-5.00 (-11.0, 1.04)	-10.2% (-19.3, -1.01)	+0.31% (-5.88, 6.49)
Serum Lactate	-1.35 (-5.28, 2.58)	-6.14 (-13.3, 1.01)	-1.01% (-5.96, 3.94)
Antibiotics	-3.58 (-7.52, 0.36)	-3.16 (-8.40, 2.08)	-4.78% (-9.70, 0.14)
Intravenous Crystalloid	-2.18 (-7.74, 3.38)	-4.23 (-11.6, 3.10)	-6.08 (-17.4, 5.25)

77

78 **Legend:** 95% CI, 95% confidence interval. SEP-1 refers to the Early Management Bundle for
79 Severe Sepsis / Septic Shock (National Quality Forum #0500). * Risk differences were estimated
80 as the average treatment effect on the treated and are expressed in terms of percentage points.

81 **eTable 11.** Treatment Effects of SEP-1 Sepsis Bundle and Components in Rebalanced Cohorts
82 with Sepsis Presenting on the Inpatient Ward or Intensive Care Unit
83

	Ward-Onset Sepsis (n = 987)		ICU-Onset Sepsis (n = 1,128)	
	Mortality Risk Difference*	95% CI	Mortality Risk Difference*	95% CI
SEP-1 Bundle	+1.70	(-15.2, 18.6)	-0.50	(-11.2, 10.2)
Blood cultures	-8.11	(-19.3, 3.04)	-1.78	(-12.6, 9.11)
Serum Lactate	+3.45	(-5.75, 12.6)	-1.30	(-10.2, 7.5)
Antibiotics	-5.79	(-14.1, 2.54)	-5.81	(-14.4, 2.83)
Intravenous Crystalloid	Utd	Utd	-4.76	(-21.6, 12.1)
	Vasopressor Days*	95% CI	Vasopressor Days*	95% CI
SEP-1 Bundle	+0.53	(-0.16, 1.22)	**1.07**	**(0.14, 2.00)**
Blood cultures	+0.29	(-0.22, 0.81)	-0.33	(-1.23, 0.57)
Serum Lactate	**+0.70**	**(0.01, 1.40)**	+0.34	(-0.34, 1.02)
Antibiotics	+0.29	(-0.11, 0.70)	-0.22	(-0.93, 0.49)
Intravenous Crystalloid	Utd	Utd	+0.35	(-0.93, 1.63)

84
85 **Legend:** ICU, intensive care unit. Utd, unable to determine. 95% CI, 95% confidence interval.
86 SEP-1 refers to the Early Management Bundle for Severe Sepsis / Septic Shock (National
87 Quality Forum #0500). * Differences in probability of in-hospital mortality and days spent on
88 vasopressors were estimated as the average treatment effect on the treated. Mortality risk
89 difference was expressed in terms of percentage points.

90 **eTable 12.** Treatment Effects of SEP-1 Sepsis Bundle and Components in Rebalanced Cohorts
91 with Time Zero of Sepsis <48 or >48 Hours After Arrival
92

	Time Zero < 48 Hours After Arrival		Time Zero > 48 Hours After Arrival	
	Mortality Risk Difference*	95% CI	Mortality Risk Difference*	95% CI
SEP-1 Bundle	+0.16	(-2.39, 2.72)	1.26	(-22.3, 24.8)
Blood cultures	-6.08	(-13.0, 0.85)	-4.16	(-15.1, 6.81)
Serum Lactate	**-5.26**	**(-9.82, -0.70)**	+7.77	(-4.80, 20.3)
Antibiotics	**-4.33**	**(-8.33, -0.32)**	-5.67	(-16.1, 4.79)
Intravenous Crystalloid	-0.92	(-7.29, 5.46)	+34.2	(-15.2, 84.4)
	Vasopressor Days*	95% CI	Vasopressor Days*	95% CI
SEP-1 Bundle	+0.37	(-0.02, 0.03)	0.13	(-1.38, 1.64)
Blood cultures	**-0.64**	**(-1.19, -0.09)**	-0.28	(-1.20, 0.64)
Serum Lactate	-0.10	(-0.45, 0.25)	0.82	(-0.04, 1.69)
Antibiotics	**-0.45**	**(-0.77, -0.12)**	-0.48	(-1.44, 0.48)
Intravenous Crystalloid	-0.48	(-1.00, 0.05)	0	(0, 0)

93
94 **Legend:** 95% CI, 95% confidence interval. SEP-1 refers to the Early Management Bundle for
95 Severe Sepsis / Septic Shock (National Quality Forum #0500). * Differences in probability of in-
96 hospital mortality and days spent on vasopressors were estimated as the average treatment effect
97 on the treated. Mortality risk difference was expressed in terms of percentage points.

98 **eTable 13.** Post Hoc Sensitivity Analyses

99

	Admitted from Home (n = 3732 matched)		Source Other than Home (n = 2077 matched)	
	Mortality Risk Difference*	95% CI	Mortality Risk Difference*	95% CI
SEP-1 Bundle	-0.04	(-3.13, 3.05)	1.33	(-3.31, 5.97)
Blood cultures	-0.59	(-5.99, 4.82)	-7.63	(-16.4, 1.14)
Serum Lactate	-4.27	(-9.70, 1.17)	-4.46	(-11.6, 2.68)
Antibiotics	-2.66	(-6.93, 1.62)	-5.28	(-11.5, 0.91)
Intravenous Crystalloid	-3.02	(-10.2, 4.21)	0.32	(-6.23, 6.87)
	Vasopressor Days	95% CI	Vasopressor Days	95% CI
SEP-1 Bundle	0.33	(0.13, 0.54)	**0.59**	**(0.27, 0.90)**
Blood cultures	-0.54	(-1.12, 0.04)	-0.40	(-1.03. 0.23)
Serum Lactate	0.02	(-0.38, 0.41)	0.01	(-0.55, 0.58)
Antibiotics	**-0.45**	**(-0.79, -0.10)**	-0.09	(-0.51, 0.33)
Intravenous Crystalloid	-0.51	(-1.15, 0.14)	-0.10	(-0.65, 0.45)
	Malignancy Absent (n = 4521 matched)		Malignancy Present (n = 978 matched)	
	Mortality Risk Difference*	95% CI	Mortality Risk Difference*	95% CI
SEP-1 Bundle	1.11	(-1.60, 3.83)	-1.23	(-8.81, 6.35)
Blood cultures	-6.01	(-12.6, 0.60)	-8.46	(-21.8, 4.92)
Serum Lactate	-0.66	(-4.59, 3.28)	-10.0	(-22.0, 0.10)
Antibiotics	-3.89	(-8.04, 0.26)	0.69	(-8.58, 9.96)
Intravenous Crystalloid	0.32	(-6.23, 6.87)	-2.01	(-16.1, 12.0)
	Vasopressor Days*	95% CI	Vasopressor Days*	95% CI
SEP-1 Bundle	0.46	(0.27, 0.65)	0.17	(-0.32, 0.66)
Blood cultures	-0.40	(-0.86, 0.06)	-0.78	(-1.84, 0.29)
Serum Lactate	0.09	(-0.25, 0.43)	-0.22	(-0.96, 0.51)
Antibiotics	**-0.48**	**(-0.83, -0.14)**	-0.11	(-0.88, 0.67)
Intravenous Crystalloid	-0.10	(-0.65, 0.45)	-0.39	(-1.65, 0.87)

100

101 **Legend:** 95% CI, 95% confidence interval. SEP-1 refers to the Early Management Bundle for
102 Severe Sepsis / Septic Shock (National Quality Forum #0500). * Differences in probability of in-
103 hospital mortality and days spent on vasopressors were estimated as the average treatment effect
104 on the treated. Mortality risk difference was expressed in terms of percentage points.